| NCT00113971 | UCB Pharma | Lupus Erythematosus, Systemic | 2005-04 | PHASE2 |
| NCT00003338 | Gilead Sciences | Lymphoma | 1997-03 | PHASE2|PHASE3 |
| NCT00004084 | Garden State Cancer Center at the Center for Molecular Medicine and Immunology|National Cancer Institute (NCI) | Leukemia|Lymphoma | 1998-04 | PHASE1|PHASE2 |
| NCT01262365 | UCB Pharma | Systemic Lupus Erythematosus | 2010-12 | PHASE3 |
| NCT00061425 | Gilead Sciences | Non-Hodgkin´s Lymphoma|Lymphoma, B-Cell | 2000-08 | PHASE1|PHASE2 |
| NCT00398372 | Stanford University|Amgen|National Institutes of Health (NIH) | Lymphoma, Non-Hodgkin|Lymphomas: Non-Hodgkin|Lymphomas: Non-Hodgkin Cutaneous Lymphoma|Lymphomas: Non-Hodgkin Diffuse Large B-Cell|Lymphomas: Non-Hodgkin Follicular + Indolent B-Cell|Lymphomas: Non-Hodgkin Mantle Cell|Lymphomas: Non-Hodgkin Marginal Zone|Lymphomas: Non-Hodgkin Peripheral T-Cell|Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia | 2000-11 | NA |
| NCT00111306 | UCB Pharma | Systemic Lupus Erythematosus | 2005-06 | PHASE3 |
| NCT00941928 | M.D. Anderson Cancer Center | Leukemia|Pediatric Cancer | 2009-07 | PHASE2 |
| NCT02306629 | UCB Biopharma S.P.R.L.|Pharmaceutical Research Associates|Richmond Pharmacology Limited|ACM Global Laboratories|Eurofins|The Doctors Laboratory Ltd | Systemic Lupus Erythematosus | 2014-11 | PHASE1 |
| NCT00042913 | Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI) | Lymphoma | 2002-05 | PHASE2 |
| NCT01279707 | Queen Mary University of London|Gilead Sciences | Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia | 2010-01 | PHASE1|PHASE2 |
| NCT00011908 | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Systemic Lupus Erythematosus | 2001-02 | PHASE1 |
| NCT01354457 | Nantes University Hospital | Acute Lymphoblastic Leukemia | 2010-11 | PHASE1|PHASE2 |
| NCT01261793 | UCB Pharma | Systemic Lupus Erythematosus | 2010-12 | PHASE3 |
| NCT01534403 | UCB Pharma | Systemic Lupus Erythematosus | 2012-01 | PHASE2 |
| NCT00383513 | UCB Pharma | Systemic Lupus Erythematosus | 2006-06 | PHASE2 |
| NCT00113802 | Gilead Sciences | Waldenstrom Macroglobulinemia | 2004-08 | PHASE2 |
| NCT00660881 | UCB Pharma | Systemic Lupus Erythematosus | 2008-05 | PHASE2 |
| NCT01219816 | Nantes University Hospital | B ALL|CD22&addition; Expression|Refractory B-ALL | 2010-11 | PHASE2 |
| NCT00004107 | Garden State Cancer Center at the Center for Molecular Medicine and Immunology|National Cancer Institute (NCI) | Leukemia|Lymphoma | 1998-02 | PHASE1|PHASE2 |
| NCT00553501 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Lymphoma | 2008-03 | PHASE2 |
| NCT00945815 | SWOG Cancer Research Network|National Cancer Institute (NCI) | Leukemia | 2010-09 | PHASE2 |
| NCT00382837 | UCB Pharma | Systemic Lupus Erythematosus | 2007-01 | PHASE3 |
| NCT00301821 | Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI) | Lymphoma | 2006-01 | PHASE2 |
| NCT00044902 | Amgen | Non-Hodgkin´s Lymphoma | | PHASE2 |
| NCT00003337 | Gilead Sciences | Lymphoma | 1997-03 | PHASE3 |
| NCT01408576 | UCB Pharma | Systemic Lupus Erythematosus | 2011-07 | PHASE3 |
| NCT00004086 | Garden State Cancer Center at the Center for Molecular Medicine and Immunology | Leukemia|Lymphoma | 1997-06 | PHASE1 |
| NCT00098839 | Children´s Oncology Group|National Cancer Institute (NCI) | Recurrent Childhood Acute Lymphoblastic Leukemia | 2005-02 | PHASE1|PHASE2 |
| NCT01449071 | UCB Pharma | Systemic Lupus Erythematosus | 2011-10 | PHASE1|PHASE2 |
| NCT01802814 | Charite University, Berlin, Germany|Australian & New Zealand Children´s Haematology+Oncology Group|St. Anna Kinderkrebsforschung (Co-Sponsor Austria)|European Organisation for Research and Treatment of Cancer - EORTC|University Hospital, Motol|Copenhagen University Hospital (Rigshospitalet) (Co-Sponsor Copenhagen)|Turku University (Co-Sponsor Finland)|Centre Hospitalier Universitaire de Nice|Our Lady´s Chilrden´s Hospital (Co-Sponsor Ireland)|Tel Aviv Sourasky Medical Centre (Co-Sponsor Israel)|Ospedale Pediatrico Bambino Gesù (Co-Sponsor Italy)|National Hospital Organization Nagoya Medical Center (Co-Sponsor Japan)|Prinses Máxima Centrum (Co-Sponsor Netherlands)|Oslo University Hospital (Co-Sponsor Oslo)|Wroclaw Medical University|Instituto Português de Oncologia de Lisboa (Co-Sponsor Lisboa)|Spanish Society of Pediatric Hematology and Oncology (SEHOP) (Co-Sponsor Spain)|University Children´s Hospital, Zurich|Central Manchester University (Co-Sponsor United Kingdom) | Acute Lymphoblastic Leukemia (ALL) | 2014-05 | PHASE3 |
| NCT00054834 | Gilead Sciences | Non-Hodgkins Lymphoma | 2003-03 | PHASE1 |